This Emgality market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing prevalence of migraines, a growing recognition of migraines as a serious condition, the approval of Emgality for both migraines and cluster headaches, a shift toward preventive treatments, and support from insurance coverage.
The projected growth during the forecast period can be attributed to expansion into emerging markets, increased awareness of migraine treatments, approval for additional indications, higher healthcare expenditure, and ongoing clinical trials. Key trends expected during this period include a growing demand for personalized medicine, technological advancements in drug delivery systems, continued progress in CGRP therapy, integration of digital health solutions, and the use of generative AI in healthcare.
The increasing prevalence of migraines is expected to drive the growth of the Emgality market. A migraine is a neurological condition that causes intense, throbbing headaches, often accompanied by symptoms such as nausea, light and sound sensitivity, and sometimes visual or sensory disturbances known as auras. The rise in migraine cases is linked to factors such as higher stress levels, lifestyle changes, environmental triggers, and increased awareness and diagnosis of the condition. Emgality works by blocking the calcitonin gene-related peptide (CGRP), reducing the frequency and severity of migraine attacks. This treatment provides long-term relief, improving the quality of life and reducing disability in frequent sufferers. For example, in May 2023, Migraine Canada reported that migraines affect 12% of Canadians (4.5 million) and over 1 billion people worldwide, with women experiencing higher prevalence rates (30% lifetime) compared to men (8%) and children (10%). Therefore, the rising prevalence of migraines is contributing to the market's growth.
A significant trend in the Emgality market is the formation of strategic partnerships that help enhance technology integration and expand market reach. These partnerships combine the resources and expertise of different organizations to achieve shared goals. For instance, in December 2023, Organon & Co., a U.S.-based healthcare company focused on women’s health, expanded its partnership with Eli Lilly to increase access to innovative migraine treatments such as Emgality and RAYVOW throughout Europe. Organon’s expertise in central nervous system disorders and its established commercial capabilities were leveraged in this collaboration. The partnership also focuses on addressing the significant impact of migraines on women, strengthening Organon’s portfolio in women's health. While Organon will oversee the distribution and promotion of the products, Lilly will maintain manufacturing and marketing authorization to ensure the effective delivery of these treatments.
In January 2023, AffaMed Therapeutics, a China-based clinical-stage biopharmaceutical company, partnered with Eli Lilly to introduce Galcanezumab in China as a preventive treatment for episodic migraines. This collaboration aims to address a critical medical need and enhance patients' quality of life, while also strengthening AffaMed's neurology portfolio and market presence. Eli Lilly, the manufacturer of Emgality, is leading the production of Galcanezumab.
The key player in the emgality market is Eli Lilly and Company.
North America was the largest region in the emgality market in 2024. The regions covered in emgality report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the emgality market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Emgality is a prescription medication used for the prevention of migraines and the treatment of episodic cluster headaches in adults. It is a monoclonal antibody that works by targeting and inhibiting calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks and pain pathways.
The main clinical indications for Emgality include migraine prevention and the treatment of cluster headaches. Migraine prevention aims to reduce the frequency and intensity of migraine episodes through treatments such as CGRP blockers, lifestyle modifications, and prophylactic medications. Emgality is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by multiple end users such as hospitals, clinics, ambulatory care facilities, and home care providers.
The emgality market research report is one of a series of new reports that provides emgality market statistics, including the emgality industry global market size, regional shares, competitors with the emgality market share, detailed emgality market segments, market trends, and opportunities, and any further data you may need to thrive in the emgality industry. This emgality market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The emgality market consists of sales of injections, prefilled syringes, and auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market size is determined by the total revenue generated by enterprises offering such products and related services within the specified geography and market. Revenues for a specific geography indicate the consumption value, representing the revenue earned from products used in that area, irrespective of their production location.
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing prevalence of migraines, a growing recognition of migraines as a serious condition, the approval of Emgality for both migraines and cluster headaches, a shift toward preventive treatments, and support from insurance coverage.
The projected growth during the forecast period can be attributed to expansion into emerging markets, increased awareness of migraine treatments, approval for additional indications, higher healthcare expenditure, and ongoing clinical trials. Key trends expected during this period include a growing demand for personalized medicine, technological advancements in drug delivery systems, continued progress in CGRP therapy, integration of digital health solutions, and the use of generative AI in healthcare.
The increasing prevalence of migraines is expected to drive the growth of the Emgality market. A migraine is a neurological condition that causes intense, throbbing headaches, often accompanied by symptoms such as nausea, light and sound sensitivity, and sometimes visual or sensory disturbances known as auras. The rise in migraine cases is linked to factors such as higher stress levels, lifestyle changes, environmental triggers, and increased awareness and diagnosis of the condition. Emgality works by blocking the calcitonin gene-related peptide (CGRP), reducing the frequency and severity of migraine attacks. This treatment provides long-term relief, improving the quality of life and reducing disability in frequent sufferers. For example, in May 2023, Migraine Canada reported that migraines affect 12% of Canadians (4.5 million) and over 1 billion people worldwide, with women experiencing higher prevalence rates (30% lifetime) compared to men (8%) and children (10%). Therefore, the rising prevalence of migraines is contributing to the market's growth.
A significant trend in the Emgality market is the formation of strategic partnerships that help enhance technology integration and expand market reach. These partnerships combine the resources and expertise of different organizations to achieve shared goals. For instance, in December 2023, Organon & Co., a U.S.-based healthcare company focused on women’s health, expanded its partnership with Eli Lilly to increase access to innovative migraine treatments such as Emgality and RAYVOW throughout Europe. Organon’s expertise in central nervous system disorders and its established commercial capabilities were leveraged in this collaboration. The partnership also focuses on addressing the significant impact of migraines on women, strengthening Organon’s portfolio in women's health. While Organon will oversee the distribution and promotion of the products, Lilly will maintain manufacturing and marketing authorization to ensure the effective delivery of these treatments.
In January 2023, AffaMed Therapeutics, a China-based clinical-stage biopharmaceutical company, partnered with Eli Lilly to introduce Galcanezumab in China as a preventive treatment for episodic migraines. This collaboration aims to address a critical medical need and enhance patients' quality of life, while also strengthening AffaMed's neurology portfolio and market presence. Eli Lilly, the manufacturer of Emgality, is leading the production of Galcanezumab.
The key player in the emgality market is Eli Lilly and Company.
North America was the largest region in the emgality market in 2024. The regions covered in emgality report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the emgality market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Emgality is a prescription medication used for the prevention of migraines and the treatment of episodic cluster headaches in adults. It is a monoclonal antibody that works by targeting and inhibiting calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks and pain pathways.
The main clinical indications for Emgality include migraine prevention and the treatment of cluster headaches. Migraine prevention aims to reduce the frequency and intensity of migraine episodes through treatments such as CGRP blockers, lifestyle modifications, and prophylactic medications. Emgality is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by multiple end users such as hospitals, clinics, ambulatory care facilities, and home care providers.
The emgality market research report is one of a series of new reports that provides emgality market statistics, including the emgality industry global market size, regional shares, competitors with the emgality market share, detailed emgality market segments, market trends, and opportunities, and any further data you may need to thrive in the emgality industry. This emgality market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The emgality market consists of sales of injections, prefilled syringes, and auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market size is determined by the total revenue generated by enterprises offering such products and related services within the specified geography and market. Revenues for a specific geography indicate the consumption value, representing the revenue earned from products used in that area, irrespective of their production location.
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Emgality Market Characteristics4. Emgality Market Trends and Strategies5. Emgality Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Emgality Pricing Analysis & Forecasts30. Global Emgality Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Emgality Market32. Recent Developments in the Emgality Market
3. Emgality Market Biologic Drug Characteristics
6. Global Emgality Growth Analysis and Strategic Analysis Framework
8. Emgality Market Segmentation
9. Global Emgality Epidemiology of Clinical Indications
10. Emgality Market Regional and Country Analysis
11. Asia-Pacific Emgality Market
12. China Emgality Market
13. India Emgality Market
14. Japan Emgality Market
15. Australia Emgality Market
16. South Korea Emgality Market
17. Western Europe Emgality Market
18. UK Emgality Market
19. Germany Emgality Market
20. France Emgality Market
21. Eastern Europe Emgality Market
22. North America Emgality Market
23. USA Emgality Market
24. Canada Emgality Market
25. South America Emgality Market
26. Middle East Emgality Market
27. Africa Emgality Market
28. Emgality Market Competitive Landscape and Company Profiles
29. Global Emgality Market Pipeline Analysis
33. Emgality Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Emgality Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on emgality market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for emgality? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The emgality market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Migraine Prevention; Cluster Headaches2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Eli Lilly and Company
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Eli Lilly and Company
